evo真人视讯

Brief News | Chairman Shi Yuanyuan and Delegation Inspect the Construction Progress of the Zone B Expansion Project of Subsidiary Junhou Bio

Date:01-14  Hits:  Belong to:News

图片.png

On the morning of January 13, 2023, Shi Yuanyuan, Chairman of Shenzhen Cell Valley, visited the construction site of the Zone B expansion project of its subsidiary Guangdong Junhou Biomedical Co., Ltd. to inspect the progress of the project. Group Deputy General Manager Xiang Hua, Assistant to the Chairman Wei Zheng, Junhou Bio Executive President Yang Borui, Vice President Feng Yaru, and Head of Logistics Shi Yunzhu accompanied the inspection.

图片.png

The Zone B expansion project of Junhou Bio is located in the Zhongshan National Health Base and is proceeding on schedule with close coordination among the construction party, supervisory party, and other stakeholders. Chairman Shi Yuanyuan emphasized the importance of maintaining a strong awareness of production safety and adhering to the "two highs and two guarantees" construction principle—high quality, high standards, safety, and meticulous attention—to ensure the orderly progress of the project, the smooth and steady advancement of all construction activities, and the earliest possible commencement of production and operations.

The Zone B expansion project of Junhou Bio is expected to be completed simultaneously with the Shenzhen Cell – South China Cell Factory by the end of February 2023, with official production slated to commence in March. By then, the South China Cell Factory will have built a 5,000-square-meter integrated production service platform, including GMP industrial-scale production lines for retroviral vectors and CAR-T/CAR-NK cell products, office areas, a smart exhibition hall, training lecture halls, and large conference rooms. Junhou Bio will have established over 1,500 square meters of B+A, C+A, and other GMP-compliant viral vector and cell product production workshops. Together, Shenzhen Cell Valley and its subsidiary Junhou Bio will undertake core technology development in the cell and gene therapy field, achieve high-capacity, high-quality modern production, build a premier service platform in the biopharmaceutical sector, and jointly contribute to the high-quality development of the industry.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@rodael.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a leading one-stop comprehensive outsourcing service provider for China’s cell and gene therapy industry. It is also among the first domestic CRO/CDMO enterprises to hold GMP-compliant industrial production capabilities for clinical-grade retroviral vectors. As a key project for the construction of Shenzhen’s public technical service platform for CRO/CDMO, the company has been listed in the city’s newly announced "20+8" strategic emerging industries initiative.
Shenzhen Cell Valley is equipped with the capacity to conduct standardized and industrialized production of GMP-grade cellular products including CAR-T cells. Its core production lines cover a full spectrum of cellular products such as CAR-T, CAR-NK, CAR-M, γδT, TIL and TCR-T. In addition, the company runs production lines for a diverse range of viral vectors (including RVV, LVV and AAV) and non-viral vectors, as well as for cellular raw materials for therapeutic development—such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software